Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK/PD Study of BMS-986331 in Healthy Participants
NCT04444050Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986331 in heart failure (HF) (16 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events up to 13 months, Number of participants with clinical laboratory abnormalities up to 46 days and 2 more. Started Jun 2020; status: completed.
02
Drugs
BMS-986331
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04444050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444050.